The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially benefiting millions of Americans struggling with obesity.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the weight loss drugs, according to a new report.